Not logged in
  Home   Markets   Shares   Funds   Portfolio   Toolbox   Charting   Alerts   Directory   
 Admin   

Thu 17 Mar 2005, 12:14 Proposed Introduction Of Additional Black
Aspen Pharmacare Holdings Limited - Proposed Introduction Of Additional Black   
Share Ownership In Aspen                                                        
ASPEN PHARMACARE HOLDINGS LIMITED                                               
(Incorporated in the Republic of South Africa)                                  
(Registration number 1985/002935/06)                                            
Share code: APN ISIN: ZAE000023586                                              
(`Aspen`)                                                                       
THE PROPOSED INTRODUCTION OF ADDITIONAL BLACK SHARE OWNERSHIP IN ASPEN          
1. INTRODUCTION                                                                 
1.1 Further to the cautionary announcement dated 15 February 2005, Aspen is     
   pleased to announce that, subject to the fulfilment of certain conditions    
precedent, which include the approval of Aspen shareholders, it has concluded
   agreements whereby it proposes to facilitate the acquisition by a broad-based
   grouping of Black Economic Empowerment (`BEE`) entities of shareholdings in  
   Aspen as follows:                                                            
1.1.1  the acquisition by Imithi Investments (Proprietary) Limited           
          (`Imithi`), the shareholders of which are set out in paragraph 2.5, of
          13 400 000 new Aspen ordinary shares and 17 600 000 new variable rate,
          voting, convertible, redeemable, cumulative Aspen preference shares   
(`the Aspen preference shares`); and                                  
   1.1.2  the acquisition by the Industrial Development Corporation of South    
          Africa Limited (`the IDC`) of 6 100 000 new Aspen ordinary shares. The
          IDC will grant Imithi a call option over these shares (`the Imithi/IDC
call option`).                                                        
The transactions in paragraphs 1.1.1 and 1.1.2 are hereinafter referred to as   
`the Imithi transaction`.                                                       
1.2 Subsequent to the Imithi transaction Aspen and/or a wholly-owned subsidiary 
of Aspen, Pharmacare Limited (`Pharmacare`), will propose a scheme of        
   arrangement (`the scheme of arrangement`) in terms of section 311 of the     
   Companies Act, 1973 (Act 61 of 1973)  (`Companies Act`) between Aspen and its
   ordinary shareholders (other than Pharmacare, Imithi, the IDC, Ceppwawu      
Pharmaceuticals Investments (Proprietary) Limited (`Ceppwawu 1`) and Ceppwawu
   Pharmaceuticals Investments 2 (Proprietary) Limited (`Ceppwawu 2`)           
   (collectively, `the excluded parties`)) to acquire, in terms of section 85 or
   89 of the Companies Act, on a pro rata basis, 6.5% of the Aspen ordinary     
shares held by those ordinary shareholders who will be participating in the  
   scheme of arrangement (`the scheme members`).                                
Imithi and Ceppwawu 1 and 2 are hereinafter referred to as `Aspen`s BEE         
entities`.                                                                      
1.3 After -                                                                     
*  implementation of the Imithi transaction;                                    
*  the scheme of arrangement;                                                   
*  exercise of the Imithi/IDC call option; and                                  
*  conversion of the Aspen preference shares,                                   
Aspen`s BEE entities (together with the 26 666 667 Aspen ordinary shares        
currently held directly by Ceppwawu 1 and 2) will hold approximately 17.9% of   
the then Aspen equity, and will enjoy the same percentage of the voting rights, 
assuming no intervening changes in the Aspen equity.                            
Pending the exercise of the Imithi/IDC call option and the conversion of the    
Aspen preference shares, Aspen`s BEE entities (together with the 26 666 667     
Aspen ordinary shares currently held directly by Ceppwawu 1 and 2) will hold    
approximately 11.9% of the then Aspen equity and 16.2% of the voting rights     
attaching to the Aspen ordinary shares and Aspen preference shares, assuming no 
intervening changes in the Aspen equity.                                        
3. THE IMITHI TRANSACTION                                                       
2.1 Rationale                                                                   
    Aspen shareholders are referred to the circular to Aspen shareholders dated 
    5 July 2004 (`the Aspen/Peu circular`) wherein Aspen specifically stated    
    that, subject to the approval of Aspen shareholders, some or all of the 21  
300 000 Aspen ordinary shares (`the Peu shares`) repurchased from Peu Health
    (Proprietary) Limited (`Peu Health`) in terms of a specific share repurchase
    (`the Peu share buy-back`) would be used to facilitate the introduction of  
    further BEE into Aspen.                                                     
Aspen is firmly committed to the promotion of BEE to achieve the            
    constitutional right to equality, increase broad-based and effective        
    participation of black people in the economy and achieve more equitable     
    income distribution. In addition, Aspen accepts that meaningful             
participation by black people in the mainstream economy is essential to     
    sustaining South Africa`s successful economic and democratic structures. The
    Imithi transaction has been designed to ensure that a meaningful portion of 
    Aspen`s equity is owned by black people and that black people have a        
meaningful role in Aspen`s operations, management and development.          
    Imithi represents a combination of a number of different entities, which    
    have formed a number of special purpose vehicles (`SPVs`) with aligned focus
    and interests. Imithi is truly broad-based, providing for the upliftment of 
the previously disadvantaged, and achieves a relevant shareholder grouping  
    with the capability of adding value to Aspen on the factory floor, in       
    management, in the boardroom and in the wider healthcare industry.          
2.2 Mechanics                                                                   
In terms of the Imithi transaction and in line with Aspen`s stated intention in 
the Aspen/Peu circular:                                                         
   2.2.1 Imithi will acquire 13 400 000 new Aspen ordinary shares at R11.00 per 
         share which will be issued by Aspen by way of a specific issue of      
shares for cash for a total consideration of R147.4 million;          
   2.2.2 Imithi will acquire 17 600 000 Aspen preference shares at R21.41, being
         the volume weighted average price (`VWAP`) per share at which Aspen    
         ordinary shares traded on the JSE Securities Exchange South Africa     
(`the JSE`) over the 30-day trading period preceding 16 March 2005     
         (`the 30-day VWAP`), which will be issued by Aspen by way of a specific
         issue of shares for cash for a total consideration of R376.8 million.  
         Imithi will have the right to require redemption or conversion of the  
Aspen preference shares into Aspen ordinary shares on a one-for-one    
         basis on the seventh anniversary after the issue of the Aspen          
         preference shares. The Aspen preference shares will vote pari passu    
         with the Aspen ordinary shares. The preference shareholders will be    
entitled to receive an annual cumulative preference cash dividend at a 
         rate equal to the prime overdraft rate of interest as charged by First 
         National Bank Limited to its most favoured corporate customers in      
         respect of unsecured overdraft facilities from time to time (`the prime
rate`) multiplied by 1 minus the corporate tax rate for the relevant   
         dividend period; and                                                   
   2.2.3 the IDC will acquire 6 100 000 new Aspen ordinary shares at R19.80 per 
         share which will be issued by Aspen by way of a specific issue of      
shares for cash, for a total consideration of R120.8 million. The issue
         price is equivalent to 92.5% of the 30-day VWAP, i.e. R21.41.          
The acquisitions by Imithi referred to in paragraph 2.2.1 and paragraph 2.2.2   
will be funded as to 2.5% of the transaction value, i.e. R13.1 million, by the  
shareholders of Imithi and the balance, i.e. R511.1 million, by the subscription
by the IDC for preference shares in Imithi.                                     
2.3 The Imithi/IDC call option                                                  
It is the intention of Imithi and the IDC that, subject to certain terms and    
conditions, the Aspen ordinary shares held by the IDC will ultimately vest in   
Imithi. To this end the IDC has granted Imithi a call option on the Aspen       
ordinary shares held by the IDC. The price at which the Imithi/IDC call option  
is granted is based upon a formula, which will result in the IDC achieving a    
predetermined rate of return. The Imithi/IDC call option is exercisable by      
Imithi over all or part of the Aspen ordinary shares held by the IDC between the
third and fourth anniversary of the date upon which the call option agreement,  
entered into between the IDC and Imithi, becomes effective.                     
2.4 The shareholders` agreement                                                 
In terms of the shareholders` agreement entered into between Imithi, each of the
individual shareholders of Imithi and Aspen,                                    
   2.4.1  Imithi will not be entitled to dispose of, or encumber, its interest  
in Aspen acquired in terms of paragraph 2.2.1 and paragraph 2.2.2     
          until the expiry of a seven-year period from the date of signature of 
          such agreement. After the expiration of the seven-year period, Imithi 
          may only dispose of, or encumber, sufficient Aspen ordinary shares to 
refinance the outstanding debt whereafter any remaining Aspen ordinary
          shares held by it shall be held for a minimum period of a further     
          three years. This results in an effective ten-year lock-in period;    
   2.4.2  Imithi has undertaken to use its best endeavours to maximise the      
additional number of Aspen ordinary shares it may hold pursuant to the
          exercise of the Imithi/IDC call option. A disposal or encumbrance of  
          such shares shall be subject to Aspen`s prior approval; and           
   2.4.3  Imithi will exercise the voting rights attached to all the Aspen      
ordinary and preference shares which it will own on a proportionate   
          basis in accordance with the instructions of its shareholders.        
2.5 Shareholders of Imithi                                                      
Details of the shareholders of Imithi are as follows:                           
2.5.1  Amalgum Investments 35 (Proprietary) Limited (`Amalgum`)              
          Amalgum, a wholly owned subsidiary of Ceppwawu Investments            
          (Proprietary) Limited, (`Ceppwawu Investments`) which in turn is a    
          wholly-owned subsidiary of the Ceppwawu Development Trust, will have a
50.4% shareholding in Imithi. Ceppwawu 1 and Ceppwawu 2, both of which
          are wholly-owned subsidiaries of Ceppwawu Investments, currently hold 
          26 666 667 Aspen ordinary shares, equivalent to 7.5% of the Aspen     
          ordinary shares in issue, net of treasury shares after the            
implementation of the Imithi transaction and the scheme of            
          arrangement. The Chemical, Energy, Paper, Printing, Wood and Allied   
          Workers Union (`Ceppwawu`) has approximately 70 000 union members and 
          represents Aspen`s unionised employees.                               
2.5.2  Little Swift Investments 214 (Proprietary) Limited, to be renamed     
          Masibulele Pharmaceuticals (Proprietary) Limited (`Masibulele`)       
          Masibulele will have a 16.5% shareholding in Imithi. Masibulele is an 
          SPV in which the shareholders are predominantly black women with      
strong connections to the healthcare industry. A minority stake in    
          Masibulele is held by two senior executives of Aspen, from previously 
          disadvantaged groups.                                                 
   2.5.3  Blue Nightingale Trading 169 (Proprietary) Limited (`Blue             
Nightingale`)                                                         
          Blue Nightingale will have a 16.5% shareholding in Imithi. Blue       
          Nightingale is an SPV comprising various professional and business    
          persons from previously disadvantaged groups and the Rockland Targeted
Development Investment Fund, which makes investments, inter alia, on  
          behalf of retirement funds affiliated to The Congress of South African
          Trade Unions.                                                         
   2.5.4  Business Ventures 670 (Proprietary) Limited (`Business Ventures`)     
Business Ventures will have a 16.5% shareholding in Imithi. Business  
          Ventures is an SPV drawing together shareholders from previously      
          disadvantaged groups with leadership positions in healthcare circles, 
          with emerging business capabilities and a development trust founded by
The Congress of Traditional Leaders of South Africa.                  
   2.5.5  IDC                                                                   
          The IDC will have a 0.1% shareholding in Imithi while it is a funder  
          of Imithi.                                                            
2.6  Conditions precedent                                                       
The Imithi transaction is subject to the fulfilment of, inter alia, the         
following conditions precedent:                                                 
   2.6.1  the granting of all the necessary regulatory approvals required for   
the implementation of the Imithi transaction (including the approval  
          by the JSE);                                                          
   2.6.2  the passing of the requisite resolutions relating to the Imithi       
          transaction by Aspen shareholders at the Aspen general meeting (`the  
Aspen general meeting`);                                              
   2.6.3  the registration of the requisite special resolutions by the Registrar
          of Companies;                                                         
   2.6.4  the granting of the Order of Court that the scheme of arrangement be  
sanctioned in terms of section 311 of the Companies Act; and          
   2.6.5  the registration of the Order of Court by the Registrar of Companies. 
3. THE SCHEME OF ARRANGEMENT                                                    
3.1 Rationale                                                                   
Subsequent to the Imithi transaction Aspen will have cash resources in      
    excess of its optimal gearing and current investment requirements. The board
    of directors of Aspen (`the Aspen Board`) has considered various            
    alternatives available in order to optimise investment returns and to       
distribute this excess cash and has taken cognisance of all its             
    stakeholders` various interests. If implemented the scheme of arrangement   
    will result in scheme members being treated equally and maintaining their   
    proportionate percentage shareholding in Aspen, relative to each other.     
3.2 Mechanics                                                                   
    Aspen and/or Pharmacare shall propose a scheme of arrangement, between Aspen
    and the scheme members to acquire 6.5% of their Aspen ordinary shares at the
    30-day VWAP, on a pro rata basis, in terms of section 85 or section 89 of   
the Companies Act at R21.41 per Aspen ordinary share. The total             
    consideration for the 20 269 560 Aspen ordinary shares (based on the current
    number of Aspen shares in issue) to be acquired will be R434.0 million.     
The Aspen ordinary shares to be acquired by Aspen and/or Pharmacare will be     
cancelled or held as treasury shares, respectively.                             
3.3 Conditions precedent                                                        
    The scheme of arrangement is conditional on, inter alia, the fulfilment of  
    the following conditions precedent:                                         
3.3.1  the passing of the requisite resolutions by Aspen shareholders to     
          approve the Imithi transaction at the Aspen general meeting;          
   3.3.2  the passing of the special resolution approving the acquisition by    
          Aspen and/or Pharmacare of Aspen ordinary shares from Aspen           
shareholders being duly passed by Aspen shareholders at the Aspen     
          general meeting;                                                      
   3.3.3  the registration of the requisite special resolutions by the Registrar
          of Companies;                                                         
3.3.4  the scheme of arrangement being approved by a majority representing   
          not less than three-fourths (75%) of the votes exercisable by scheme  
          members present and voting either in person or by proxy at the meeting
          to be held to approve the scheme of arrangement (`the scheme          
meeting`);                                                            
   3.3.5  the High Court of South Africa (Witswatersrand Local Division)        
          sanctioning the scheme of arrangement in terms of the Companies Act   
          and the registration of such Order by the Registrar of Companies; and 
3.3.6  any other regulatory approvals that may be required.                  
4. UTILISATION OF PROCEEDS                                                      
Aspen intends to utilise the R 376.8 million raised by the issue of the Aspen   
preference shares in an optimal manner.  Given current circumstances and funding
requirements this would entail an investment in premium rated preference shares.
R268.2 million raised from the issue of Aspen ordinary shares will be used      
towards funding the scheme of arrangement. The balance of R165.8 million        
(assuming no intervening changes in the number of Aspen ordinary shares in      
issue) required to fund the scheme of arrangement will be obtained from Aspen`s 
existing cash resources.                                                        
5. THE RESULTANT SHAREHOLDER STRUCTURE OF ASPEN                                 
The shareholder structure of Aspen post implementation of the proposed BEE      
transaction and the scheme of arrangement is set out below.                     
SEE PRESS FOR DETAILS                                                           
* Listed on the JSE                                                             
The percentages in the above structure are stated as a percentage of the total  
Aspen equity in issue, net of treasury shares and subsequent to the Imithi      
transaction and the scheme of arrangement and assuming full conversion of the   
Aspen preference shares.                                                        
6. ACCOUNTING TREATMENT                                                         
The principle underlying the accounting treatment is compliance with South      
African Statements of Generally Accepted Accounting Practice (`GAAP`), which is 
based on International Financial Reporting Standards (`IFRS`). GAAP and/or IFRS 
may require a transaction to be accounted for in a different manner to its legal
substance and form.                                                             
Any possible effects of IFRS 2 (Share-based Payments) on the Imithi transaction 
have not been taken into account.                                               
It is also assumed that the fair value of underlying debt and equity components 
of the preference shares is equal to the issue price for the purposes of IAS 32 
(Financial Instruments: Disclosure and Presentation) and IAS 39 (Financial      
Instruments: Recognition and Measurement).                                      
7. PRO FORMA FINANCIAL EFFECTS                                                  
The unaudited pro forma financial effects set out in the table below have been  
prepared to assist Aspen shareholders to assess the impact of the Imithi        
transaction and the scheme of arrangement on the earnings per share (`EPS`),    
headline EPS (`HEPS`) and the net asset value (`NAV`) and the tangible NAV      
(`NTAV`) per Aspen ordinary share. These unaudited pro forma financial effects  
have been disclosed in terms of the Listings Requirements of the JSE and do not 
constitute a representation of the future financial position or results of Aspen
on implementation of the Imithi transaction and the scheme of arrangement. The  
unaudited pro forma financial effects have been prepared for illustrative       
purposes only. The material assumptions are set out in the notes following the  
table.                                                                          
                                            Pro                                 
Forma                               
                        Pro Forma           `After`                             
                        `After`             the                                 
                 Actua  the Imithi          Imithi    Cumula                    
l      transactio Change   transact  tive                      
                 `Befo  n          %        ion and   change                    
                 re`                        the       %                         
                                            scheme                              
of                                  
                                            arrangem                            
                                            ent                                 
   EPS (cents)                                                                  
for the six                                                                  
   months ended  63.7   62.0       (2.7)    62.1      (2.5)                     
   31 December                                                                  
   2004                                                                         
HEPS (cents)                                                                 
   for the six                                                                  
   months ended  63.7   62.0       (2.7)    62.1      (2.5)                     
   31 December                                                                  
2004                                                                         
   NAV (cents)                                                                  
   as at 31      281.6  357.2      26.9     250.0     (11.2)                    
   December                                                                     
2004                                                                         
   NTAV (cents)                                                                 
   as at 31      58.2   146.0      150.9    26.1      (55.1)                    
   December                                                                     
2004                                                                         
   Number of                                                                    
   shares in                                                                    
   issue at 31   338.0  357.5               337.3                               
December                                                                     
   2004  (`m)                                                                   
   Weighted                                                                     
   average                                                                      
number of                                                                    
   shares in                                                                    
   issue for     340.8  360.3               340.0                               
   the six                                                                      
months ended                                                                 
   31 December                                                                  
   2004 (`m)                                                                    
Notes                                                                           
1. All figures in the Actual `Before` column are based on the published interim 
   results for the six months ended 31 December 2004 (`the interim results`).   
2. The unaudited Pro Forma `After` EPS and HEPS calculations are based on the   
   following assumptions:                                                       
2.1  the Imithi transaction and the acquisition by Aspen of 20 269 560 Aspen 
        ordinary shares in terms of the scheme of arrangement  were implemented 
        on 1 July 2004;                                                         
   2.2  the proceeds received from the issue of 17 600 000 Aspen preference     
shares in terms of the Imithi transaction were invested in preference   
        shares with an annual after-tax yield of 64% of the prime rate for the  
        six months to 31 December 2004;                                         
   2.3  STC at 12.5% has been taken into account on all dividends payable and   
receivable; and                                                         
   2.4  the costs of the Imithi transaction and the scheme of arrangement have  
        been offset against the share premium.                                  
3. The unaudited pro forma `After` NAV and NTAV calculations have been based on 
the additional assumption that the Imithi transaction and the scheme of      
   arrangement were implemented on 31 December 2004.                            
4. The benefit of the reduced number of ordinary shares in issue as a result of 
   the Peu share buy-back was included in the interim results. Of the total     
dilution in HEPS of 2.5%, 2.1% arises as a consequence of the 13 400 000     
   Aspen ordinary shares to be issued to Imithi in substitution of an equal     
   number of Peu shares (refer to paragraph 2.1).                               
8. OPINIONS AND RECOMMENDATIONS                                                 
The Aspen Board has designed the Imithi transaction to ensure that it is in line
with the BEE strategy of Aspen as set out in paragraph 2.1 and that it will be  
positive for the future development of Aspen`s business. The Aspen Board        
believes that the Imithi transaction and the scheme of arrangement will be in   
the best interests of Aspen and all its stakeholders.                           
The Aspen Board, save for Mr Buthelezi, a trustee of The Ceppwawu Development   
Trust and director of Ceppwawu Investments, who recused himself owing to        
Amalgum`s involvement in the Imithi transaction, unanimously recommends that    
shareholders vote in favour of the resolutions to be considered at the Aspen    
general meeting and in favour of the scheme of arrangement at the scheme        
meeting. In respect of their own holdings of Aspen ordinary shares, the members 
of the Aspen Board intend to vote in favour of the resolutions to be presented  
at the Aspen general meeting and in favour of the scheme of arrangement at the  
scheme meeting.                                                                 
9. NOMINATION OF DIRECTOR                                                       
Dr. Judy Dlamini has been nominated by Imithi to the Aspen board.  Dr. Dlamini  
led the Imithi team in negotiating the Imithi transaction.  She is a qualified  
medical doctor with corporate finance and business experience.                  
10. BLACK EMPLOYEES                                                             
The Aspen Board is considering various options for the effective implementation 
of a workers` trust and a share scheme for senior black employees.  An          
announcement in this regard will be made as soon as details are available.      
11. WITHDRAWAL OF CAUTIONARY ANNOUNCEMENT                                       
Aspen shareholders are referred to the cautionary announcement dated 15 February
2005 and are advised that they are no longer required to exercise caution in    
their dealings in Aspen ordinary shares.                                        
12. FURTHER DETAILS                                                             
A circular setting out the full details of the Imithi transaction and the scheme
of arrangement, which circular will incorporate the notices of the Aspen general
meeting and the scheme meeting, will be posted to Aspen shareholders in due     
course.                                                                         
Woodmead                                                                        
17 March 2005                                                                   
   Transaction advisor   Sponsor to Aspen     Legal advisor                     
   to Aspen              Investec Bank        to Aspen                          
   Investec Corporate                         Werksmans Inc.                    
Finance                                                                      
   Transaction advisor   Legal advisor to     Funder to                         
   to Imithi             Imithi               Imithi                            
   Andisa Capital        Bowman Gifillan      IDC                               
Attorneys                                              
Profile Group (Pty) Ltd. has taken care in preparing all information on this website, but does not accept any liability for errors or out-of-date information.
Other Profile Group sites: FundsData Online (unit trust data)  |  Profile Group corporate site
[  Terms of Use |  Privacy Policy |  PAIA manual |  FAQs/Help |  Site Map |  © Copyright Reserved 2026  ]
  


Powered by ProfileData

Profile Mobile App Google Play Store Apple App Store


Follow us on: